To test this, we chose thyroid cancer cell lines containing mutations in the commonly mutated oncogenes; BRAF, RAS, and PIK3CA (Table 1), along with two cell lines sensitive to dasatinib; the BRAF mutant, BCPAP, and the RAS-mutant, Cal6210. This evidence concerns the gene BRAF and thyroid cancer.